Stockholm October 4, 2011

Head of R&D Peter Edman to leave Sobi

Peter Edman, Head of R&D, will leave Sobi as of December 31, 2011.

"The years in Sobi have been exciting and rewarding", says Peter Edman. "During this time we have restructured and focused the research operations on recombinant protein projects within rare diseases, and taken the decision to advance three development projects into phase III. I have the greatest respect for the knowledge and competence within Sobi and it was not an easy decision to leave."

"I want to thank Peter for his contributions to Sobi and we wish him well in his future endeavors" says Geoffrey McDonough, President and CEO of Sobi. "We remain committed to delivering our phase III and early stage development pipeline. We will also utilize our unique competences in protein biochemistry and biologics manufacturing to acquire new late stage assets in the rare disease area. We will now start the process to bring in a senior individual with the appropriate skills to build on this foundation for the future."

For additional information, please contact:
Åsa Stenqvist, Head of Communications and Investor Relations
Tel.: +46 8 697 21 88

About Swedish Orphan Biovitrum (Sobi)
Sobi is a leading European specialty pharmaceutical company focused on providing and developing pharmaceuticals for patients with rare diseases and significant medical needs. The portfolio comprises about 60 marketed products, as well as projects in late clinical phase. Key therapeutic areas are hematological diseases, autoimmune diseases, hereditary metabolic disorders and therapeutic oncology. In 2010 Sobi had revenues of SEK 1.9 billion and approximately 500 employees. The share (STO: SOBI) is listed on NASDAQ OMX Stockholm. For more information please visit www.sobi.com

The above information has been made public in accordance with the Swedish Securities Market Act and/or the Financial Instruments Trading Act. The information was released for public distribution on October 4, 2011 at 8.30 CET.